Applications

1456 – 17p Deletion Testing for Access to Venetoclax in Patients with Relapsed/Refractory Chronic Lymphoid Leukaemia

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

Venetoclax is a BCL-2 inhibitor listed on the Australian Register of Therapeutic Goods (ARTG). The TGA-approved indications are as a treatment for:

  • Patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) with 17p-del, or
  • Patients with relapsed or refractory CLL for whom there are no other suitable treatment options.

Type: Co-dependent technology

Medical condition this application addresses

Chronic lymphoid leukaemia (CLL), which is also known as B-cell Chronic lymphoid leukaemia (B-CLL), is a specific type of leukaemia, a group of cancers usually originated in bone marrow and resulting in abnormally high numbers of white blood cells. The presence of a 17p deletion is associated with a significantly poorer prognosis, and patients harbouring a 17p deletion show marked resistance to genotoxic chemotherapies recommended as first-line treatment for CLL.

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: 8 June 2017
  • MSAC meeting: 
    • 6 - 7 April 2017
    • 27 July 2017
    • 22 - 23 November 2018